New pill targets Alzheimer's in High-Risk gene carriers

NCT ID NCT04693520

Completed Disease control Sponsor: Alzheon Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called ALZ-801 in 84 people with early Alzheimer's who carry the APOE4 gene variant, which increases risk. Researchers measured changes in blood and brain scan markers of Alzheimer's over 65 weeks to see if the drug slows disease progression. The goal was to evaluate safety and effects on key Alzheimer's-related proteins.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY ALZHEIMER'S DISEASE

Contacts and locations

Locations

Brain Research Center

's-Hertogenbosch, Netherlands
Brain Research Center

Amsterdam, Netherlands
Brain Research Center

Zwolle, Netherlands
Motol University Hospital

Prague, Czechia
St. Anne's University Hospital

Brno, Czechia
Vestra Clinics

Rychnov nad Kněžnou, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.